Sarcomas are forms of cancer that comprise tumors of the connective and structural tissue of the body and mainly affect children and young adults. Pediatric soft tissue sarcomas (STS) are a heterogeneous group of malignant tumors constituting about 7% of all cancer cases. Rhabdomyosarcomas (RMS) constitute about half of all soft tissue sarcomas in children, the rest being constituted by non- rhabdomyosarcoma soft tissue sarcomas (NRSTS). The estimated 5-year survival rate is around 65.6% in children and young adults, Rhabdomyosarcoma being as low as 59.2% in some cases.
Current forms of therapy consist of neo-adjuvant chemotherapy, surgical intervention and radiotherapy. But new therapy is required, especially as in the last 40 years little has changed in the treatment and management of this form of pediatric cancer disease. This Research Topic would like to focus on the characteristics and biological behavior of STS disease. It is essential to combine the diverse investigations that are performed at a molecular/cellular level from basic research to clinical translation spanning genomic and proteomic analysis and clinical management to produce better patient outcomes.
This Research Topic welcomes original research articles, hypotheses, and theories, as well as reviews and mini-reviews surrounding:
• Multi-Omic analysis in the development of STS.
• The clinical pathological or radiological imaging STS
• Therapy resistance and the future of treatments of STS.
• The changes in clinical management of STS and potential improvements to be made.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Sarcomas are forms of cancer that comprise tumors of the connective and structural tissue of the body and mainly affect children and young adults. Pediatric soft tissue sarcomas (STS) are a heterogeneous group of malignant tumors constituting about 7% of all cancer cases. Rhabdomyosarcomas (RMS) constitute about half of all soft tissue sarcomas in children, the rest being constituted by non- rhabdomyosarcoma soft tissue sarcomas (NRSTS). The estimated 5-year survival rate is around 65.6% in children and young adults, Rhabdomyosarcoma being as low as 59.2% in some cases.
Current forms of therapy consist of neo-adjuvant chemotherapy, surgical intervention and radiotherapy. But new therapy is required, especially as in the last 40 years little has changed in the treatment and management of this form of pediatric cancer disease. This Research Topic would like to focus on the characteristics and biological behavior of STS disease. It is essential to combine the diverse investigations that are performed at a molecular/cellular level from basic research to clinical translation spanning genomic and proteomic analysis and clinical management to produce better patient outcomes.
This Research Topic welcomes original research articles, hypotheses, and theories, as well as reviews and mini-reviews surrounding:
• Multi-Omic analysis in the development of STS.
• The clinical pathological or radiological imaging STS
• Therapy resistance and the future of treatments of STS.
• The changes in clinical management of STS and potential improvements to be made.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
